Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
NCT03229096
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Chemotherapy Effect
Chemotherapeutic Toxicity
Gastric Cancer
Interventions
DRUG:
Apatinib plus XELOX
Sponsor
Shanghai Zhongshan Hospital